Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis

Boni E Elewski, Andrew Blauvelt, Gaia Gallo, Eric Wolf, Missy McKean-Matthews, Russel Burge, Joseph F Merola, Alice B Gottlieb, Lyn C Guenther, Boni E Elewski, Andrew Blauvelt, Gaia Gallo, Eric Wolf, Missy McKean-Matthews, Russel Burge, Joseph F Merola, Alice B Gottlieb, Lyn C Guenther

Abstract

Introduction: The lifetime incidence of nail psoriasis in patients with psoriasis is 80-90%, with 23-27% of patients having nail psoriasis at any given time. Nail psoriasis is even more prevalent in patients with comorbid psoriatic arthritis. Complete psoriasis clearance, an achievable therapeutic goal, should ideally include the resolution of nail psoriasis. Here, we assessed simultaneous skin and nail clearance in patients with psoriasis across five head-to-head trials comparing ixekizumab with other biologics.

Methods: Data were assessed in patients with moderate-to-severe psoriasis (with or without psoriatic arthritis) with nail psoriasis at baseline from the IXORA-R, IXORA-S, UNCOVER-2, UNCOVER-3, and SPIRIT-H2H trials. Ixekizumab patients received IXEQ2W to week 12 and IXEQ4W beyond week 12. PASI 100 depicted complete skin clearance, and PGA-F 0 (IXORA-R) or NAPSI 0 (all other trials) depicted complete nail clearance. Treatment comparisons were evaluated using the Cochran-Mantel-Haenszel test. Non-responder imputation was used for missing data.

Results: Ixekizumab achieved significantly greater simultaneous skin and nail complete clearance than etanercept (UNCOVER-2: p < 0.001 and UNCOVER-3: p < 0.001) at week 12, demonstrating an efficacious and rapid response. Across all five head-to-head trials, ixekizumab achieved a high rate of simultaneous skin and nail clearance (range: 28.6-45.9% of patients) by week 24 that was maintained up to week 52 (range: 40.5-51.4% of patients). Ixekizumab achieved numerically greater simultaneous complete clearance than guselkumab at week 24 (p = 0.079), but statistically significant greater simultaneous clearance compared to ustekinumab (p < 0.001) and adalimumab (p = 0.006) at week 24 and week 52 (p < 0.001 and p = 0.007, respectively).

Conclusion: In five head-to-head trials, ixekizumab-treated patients had higher rates of simultaneous complete skin and nail clearance compared to etanercept, guselkumab, ustekinumab, and adalimumab, thereby reinforcing ixekizumab's ability to achieve high levels of efficacy in multiple domains of psoriatic disease.

Trial registration: NCT01474512, NCT01597245, NCT01646177, NCT03573323, NCT02561806, and NCT03151551.

Keywords: Adalimumab; Etanercept; Guselkumab; IL 17A inhibitor; Ixekizumab; Moderate-to-severe psoriasis; Psoriatic arthritis; Ustekinumab.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Simultaneous skin and nail clearance at Week 12. Ixekizumab achieved significantly greater simultaneous PASI 100 and NAPSI 0 clearance vs. etanercept (a,b) at week 12. All data are presented as % response. IXE ixekizumab, ETA etanercept, PASI Psoriasis Area Severity Index, n number of patients, NAPSI Nail Psoriasis and Severity Index
Fig. 2
Fig. 2
Simultaneous skin and nail clearance at Week 24. Ixekizumab achieved numerically greater simultaneous PASI 100 and PGA-F 0 clearance vs. guselkumab (a) and significantly greater simultaneous PASI 100 and NAPSI 0 clearance vs. ustekinumab (b) and adalimumab (c) by week 24. All data are presented as % response. IXE ixekizumab, ADA adalimumab, UST ustekinumab, GUS guselkumab, PASI Psoriasis Area Severity Index, n number of patients, NAPSI Nail Psoriasis and Severity Index, PGA-F Physician’s Global Assessment-Fingernails
Fig. 3
Fig. 3
Simultaneous skin and nail clearance at Week 52. Ixekizumab achieved significantly greater simultaneous PASI 100 and NAPSI 0 clearance vs. ustekinumab (a) and adalimumab (b) at Week 52. All data are presented as % response. IXE ixekizumab, ADA adalimumab, UST ustekinumab, PASI Psoriasis Area Severity Index, n number of patients, NAPSI Nail Psoriasis and Severity Index
Fig. 4
Fig. 4
Simultaneous skin and nail clearance with ixekizumab up to Week 52. Simultaneous skin and nails clearance in psoriasis patients with ixekizumab treatment at Weeks 12 (UNCOVER-2 and -3), 24 (IXORA-R and -S), and 52 (IXORA-S). All data are presented as % response. PASI Psoriasis Area Severity Index, n number of patients, NAPSI Nail Psoriasis and Severity Index, PGA-F Physician’s Global Assessment-Fingernails
Fig. 5
Fig. 5
Ixekizumab complete skin response (PASI 100) with no residual disease in nails. Integrated analysis of UNCOVER-1 and UNCOVER-2 in patients with moderate-to-severe plaque psoriasis. Fifty patients out of 72 (69.4%) PASI 100 Week 52 responders had no residual disease in nails. PASI Psoriasis Area Severity Index, n number of patients, NAPSI Nail Psoriasis and Severity Index

References

    1. Kimball AB, Gladman D, Gelfand JM, et al. National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–1042. doi: 10.1016/j.jaad.2008.01.006.
    1. Sampogna F, Tabolli S, Abeni D. Investigators IMPRoVEI. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta Derm Venereol. 2012;92(3):299–303. doi: 10.2340/00015555-1273.
    1. Liu L, Lu J, Allan BW, et al. Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A. J Inflamm Res. 2016;9:39–50. doi: 10.2147/JIR.S100940.
    1. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541–551. doi: 10.1016/S0140-6736(15)60125-8.
    1. Gordon KB, Colombel JF, Hardin DS. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(21):2102. doi: 10.1056/NEJMc1612334.
    1. Paul C, Griffiths CEM, van de Kerkhof PCM, et al. Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study. J Am Acad Dermatol. 2019;80(1):70–9.e3. doi: 10.1016/j.jaad.2018.06.039.
    1. Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021;184(6):1047–1058. doi: 10.1111/bjd.19509.
    1. Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–131. doi: 10.1136/annrheumdis-2019-215386.
    1. Leonardi C, Reich K, Foley P, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther (Heidelb) 2020;10(3):431–447. doi: 10.1007/s13555-020-00367-x.
    1. Blauvelt A, Wu JJ, Armstrong A, Menter A, Liu C, Jacobson A. Importance of complete skin clearance in psoriasis as a treatment goal: implications for patient-reported outcomes. J Drugs Dermatol. 2020;19(5):487–492. doi: 10.36849/JDD.2020.4957.
    1. Manalo IF, Gilbert KE, Wu JJ. Time to raise the bar to psoriasis area severity index 90 and 100. J Drugs Dermatol. 2015;14(10):1086–1088.
    1. Augustin M, Reich K, Blome C, Schäfer I, Laass A, Radtke MA. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol. 2010;163(3):580–585. doi: 10.1111/j.1365-2133.2010.09831.x.
    1. Sampogna F, Linder D, Piaserico S, et al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014;94(4):411–414. doi: 10.2340/00015555-1731.
    1. Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. doi: 10.1111/dth.12589.
    1. Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117–122. doi: 10.1016/j.jaad.2019.08.026.
    1. Baran R. The burden of nail psoriasis: an introduction. Dermatology. 2010;221(Suppl 1):1–5. doi: 10.1159/000316169.
    1. Langenbruch A, Radtke MA, Krensel M, Jacobi A, Reich K, Augustin M. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–1128. doi: 10.1111/bjd.13272.
    1. Scarpa R, Soscia E, Peluso R, et al. Nail and distal interphalangeal joint in psoriatic arthritis. J Rheumatol. 2006;33(7):1315–1319.
    1. Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486–489. doi: 10.1111/ced.12805.
    1. Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis, the unknown burden of disease. J Eur Acad Dermatol Venereol. 2014;28(12):1690–1695. doi: 10.1111/jdv.12368.
    1. Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269. doi: 10.1001/jamadermatol.2019.4029.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner